News - Actos

Filter

Current filters:

Actos

Popular Filters

Takeda ordered to pay $6 billion damages in Actos trial

Takeda ordered to pay $6 billion damages in Actos trial

08-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical has been ordered to pay $6 billion in punitive damages…

ActosDiabetesEli Lilly and CompanyJapanJudgeLegalMajorPharmaceuticalPyridinesTakeda NycomedThiazolidinedionesUSA

US Judge throws out verdict in Takeda Actos case

03-05-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Takeda considering options over US Actos court ruling

29-04-2013

The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Watson sues US FDA regarding generic Actos approval delay

16-08-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says it has filed suit against the US Food and…

ActosDiabetesGenericsLegalNorth AmericaTakeda PharmaceuticalsWatson Pharmaceuticals

US FDA again delays action on Takeda's alogliptin diabetes drug

26-04-2012

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has received a complete response…

ActosalogliptinDiabetesNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

EC backs continued use of pioglitazone drugs for diabetes

10-01-2012

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO 4502) said yesterday that the European Commission…

ActosDiabetesEuropePharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Takeda ends Daxas co-promotion with MSD; Actos law suits

03-01-2012

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review

24-10-2011

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

New twist in diabetes drugs could reduce life-threatening side effects

12-09-2011

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter,…

ActosAvandiaDiabetesGlaxoSmithKlinePharmaceuticalResearchTakeda Pharmaceuticals

Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems

01-08-2011

Given the suspension of use in France and Germany and ongoing deliberations at the US Food and and Drug…

ActosByettaDiabetesJanuviaMarkets & MarketingPharmaceuticalVictoza

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top